By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > CNS stimulants > Dexmethylphenidate and serdexmethylphenidate > Dexmethylphenidate / Serdexmethylphenidate Dosage
CNS stimulants
https://themeditary.com/dosage-information/dexmethylphenidate-serdexmethylphenidate-dosage-11147.html

Dexmethylphenidate / Serdexmethylphenidate Dosage

Drug Detail:Dexmethylphenidate and serdexmethylphenidate (Dexmethylphenidate and serdexmethylphenidate [ dex-meth-il-fen-i-date-and-ser-dex-meth-il-fen-i-date- ])

Drug Class: CNS stimulants

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Attention Deficit Disorder

Doses are expressed as serdexmethylphenidate/dexmethylphenidate

Initial dose: 39.2 mg/7.8 mg orally once a day

  • After 1 week, increase to 52.3 mg/10.4 mg orally once a day
Maintenance dose: 52.3 mg/10.4 mg orally once a day
Maximum dose: 52.3 mg/10.4 mg per day

Comments:
  • Pretreatment screening for the presence of cardiac disease should be performed prior to initiating therapy.
  • Dosing is once a day in the morning.
  • Treatment of Attention Deficit Hyperactivity Disorder (ADHD) may be needed for an extended period; periodically re-evaluate long-term use and adjust dose as needed.

Use: For the treatment of ADHD.

Usual Pediatric Dose for Attention Deficit Disorder

Doses are expressed as serdexmethylphenidate/dexmethylphenidate

6 to 12 years:
Initial dose: 39.2 mg/7.8 mg orally once a day

  • After 1 week, may increase to 52.3 mg/10.4 mg orally once a day or decrease to 26.1 mg/5.2 mg orally once a day depending on response and tolerability
Maintenance dose: 26.1 mg/5.2 mg to 52.3 mg/10.4 mg orally once a day
Maximum dose: 52.3 mg/10.4 mg per day

13 years or older:
Initial dose: 39.2 mg/7.8 mg orally once a day in the morning
  • After 1 week, increase to 52.3 mg/10.4 mg orally once a day
Maintenance dose: 52.3 mg/10.4 mg orally once a day
Maximum dose: 52.3 mg/10.4 mg per day

Comments:
  • Pretreatment screening for the presence of cardiac disease should be performed prior to initiating therapy.
  • Dosing is once a day in the morning.
  • Treatment of Attention Deficit Hyperactivity Disorder (ADHD) may be needed for an extended period; periodically re-evaluate long-term use and adjust dose as needed.

Use: For the treatment of ADHD in patients 6 years or older.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

Use with caution; there is no experience with use in patients with hepatic impairment

Dose Adjustments

If Switching from Other Methylphenidate Products:

  • Discontinue methylphenidate and titrate with this drug as described in Usual Dose
  • Methylphenidate products should not be substituted on a mg-per-mg basis due to their differing pharmacokinetic profiles

Dose Reduction and Discontinuation:
  • Therapy should be reduced or discontinued if paradoxical aggravation or other adverse reactions occur
  • Pediatric patients should periodically discontinue/interrupt therapy to assess condition.
  • If improvement is not observed after appropriate dosage adjustment over a 1-month period, the drug should be discontinued

Precautions

US BOXED WARNING: ABUSE AND DEPENDENCE

  • CNS stimulants, including this drug, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence.
  • Assess risk of abuse prior to prescribing and monitor for signs of abuse and dependence during therapy.

CONTRAINDICATIONS:
  • Hypersensitivity to active substances, methylphenidate, or other product excipients
  • Concomitant use with monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation because of the risk of hypertensive crisis

Safety and efficacy have not been established in patients younger than 6 years.

Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule II

Dialysis

Data not available

Other Comments

Administration advice:

  • Take orally once a day in the morning with or without food
  • Capsules may be take whole, or opened and sprinkled into 50 mL of water or over 2 tablespoons of applesauce

Storage requirements: Protect from moisture

Reconstitution/preparation techniques:
  • Capsules may be opened and sprinkled into 50 mL of water or over 2 tablespoons of applesauce; all drug/food mixtures should be consumed immediately or within 10 minutes; do not store for future use

General:
  • This coformulated drugs contains the prodrug serdexmethylphenidate with immediate-release dexmethylphenidate; this coformulated product is intended to provide immediate and prolonged duration of action.
  • Because CNS stimulants have been associated with weight loss and slowing of growth in pediatric patients, carefully monitor growth, therapy may need to be interrupted in patients who are not growing or gaining height or weight as expected.
  • Periodically reevaluate long-term use and adjust doses as needed.

Monitoring:
  • Pre-Treatment: Screen for the presence of cardiac disease, including a physical exam and careful family history; assess risk of abuse
During Therapy:
  • Monitor height and weight in pediatric patients
  • Monitor blood pressure and heart rate
  • Monitor for abuse and dependence
  • Monitor for psychotic or manic symptoms

Patient advice:
  • Patients should be instructed to read the US FDA-approved patient labeling (Medication Guide).
  • Patients should understand that this is a controlled substance and it can be abused; this drug should be stored in a safe place and disposed of promptly when no longer needed.
  • Patients should understand the serious cardiovascular risks associated with use and should know to contact their healthcare provider immediately if they develop symptoms such as chest pain with exertion, unexplained syncope, or any other symptoms suggestive of cardiac disease.
  • Patients/caregivers should be aware that this drug may cause slowing of growth and weight loss; height and weight should be routinely monitored in pediatric patients.
  • Patients should be instructed to contact their healthcare provider immediately with any signs of circulation problems in fingers and toes, priapism, or any new or worsening psychotic or manic symptoms.
Share this Article
Latest News
Medical News

Obesity, unhealthy lifestyles may cause heart to age by 5–45 years

May 08, 2025
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Heart disease: Just 3 minutes of 'incidental activity' may lower...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by